Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
Abbott's tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at $402 per share is now scheduled to expire on Oct. 3.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Agilent received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's shares at a discount to market price.
Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock.
Roche said that based on preliminary results, Foundation Medicine shareholders tendered a total of 17.5 million shares, not including 1.9 million shares that were tendered by notice of guaranteed delivery.
Roche will acquire a majority stake in Foundation Medicine and directly invest in R&D.
The offer for 15.6 million shares of Foundation's common stock at $50 per share has been extended to midnight EST at the end of the day April 6.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.